DMAC
Price:
$5.285
Market Cap:
$225.99M
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutic...[Read more]
Industry
Biotechnology
IPO Date
2012-08-03
Stock Exchange
NASDAQ
Ticker
DMAC
According to DiaMedica Therapeutics Inc.’s latest financial reports and current stock price. The company's current ROE is -43.68%. This represents a change of 298.08% compared to the average of -10.97% of the last 4 quarters.
The mean historical ROE of DiaMedica Therapeutics Inc. over the last ten years is -61.17%. The current -43.68% ROE has changed -28.60% with respect to the historical average. Over the past ten years (40 quarters), DMAC's ROE was at its highest in in the September 2017 quarter at 2.90%. The ROE was at its lowest in in the March 2017 quarter at -24719.60%.
Average
-61.17%
Median
-40.46%
Minimum
-533.17%
Maximum
315.11%
Discovering the peaks and valleys of DiaMedica Therapeutics Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 315.10%
Maximum Annual ROE = 315.11%
Minimum Annual Increase = -252.07%
Minimum Annual ROE = -533.17%
Year | ROE | Change |
---|---|---|
2023 | -37.96% | -11.66% |
2022 | -42.97% | 39.18% |
2021 | -30.87% | -34.66% |
2020 | -47.25% | -66.20% |
2019 | -139.81% | 315.10% |
2018 | -33.68% | -93.68% |
2017 | -533.17% | 198.82% |
2016 | -178.42% | -252.07% |
2015 | 117.33% | -62.77% |
2014 | 315.11% | -158.75% |
The current ROE of DiaMedica Therapeutics Inc. (DMAC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-37.27%
5-year avg
-59.77%
10-year avg
-61.17%
DiaMedica Therapeutics Inc.’s ROE is greater than Milestone Pharmaceuticals Inc. (-151.81%), less than Seres Therapeutics, Inc. (60.75%), greater than Inhibikase Therapeutics, Inc. (-350.62%), greater than Oncolytics Biotech Inc. (-141.94%), greater than scPharmaceuticals Inc. (-314.97%), greater than aTyr Pharma, Inc. (-56.83%), greater than Lyra Therapeutics, Inc. (-178.68%), greater than Centessa Pharmaceuticals plc (-52.22%), greater than Iovance Biotherapeutics, Inc. (-58.43%), less than X4 Pharmaceuticals, Inc. (0%), greater than Galera Therapeutics, Inc. (-32.51%), less than Terns Pharmaceuticals, Inc. (14.34%), greater than Day One Biopharmaceuticals, Inc. (-32.76%), greater than HOOKIPA Pharma Inc. (-22.40%), greater than null (-49.25%),
Company | ROE | Market cap |
---|---|---|
-151.81% | $98.92M | |
60.75% | $165.51M | |
-350.62% | $199.23M | |
-141.94% | $74.38M | |
-314.97% | $169.39M | |
-56.83% | $131.12M | |
-178.68% | $11.21M | |
-52.22% | $2.21B | |
-58.43% | $2.26B | |
0% | $97.52M | |
-32.51% | $1.64M | |
14.34% | $488.82M | |
-32.76% | $1.27B | |
-22.40% | $17.67M | |
-49.25% | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like DiaMedica Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like DiaMedica Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is DiaMedica Therapeutics Inc.'s ROE?
How is the ROE calculated for DiaMedica Therapeutics Inc. (DMAC)?
What is the highest ROE for DiaMedica Therapeutics Inc. (DMAC)?
What is the 3-year average ROE for DiaMedica Therapeutics Inc. (DMAC)?
What is the 5-year average ROE for DiaMedica Therapeutics Inc. (DMAC)?
How does the current ROE for DiaMedica Therapeutics Inc. (DMAC) compare to its historical average?